Iron, Oxidative Damage and Ferroptosis in Rhabdomyosarcoma

Alessandro Fanzani * and Maura Poli *

Department of Molecular and Translational Medicine (DMMT), University of Brescia, Viale Europa 11, 25123 Brescia, Italy

* Correspondence: alessandro.fanzani@unibs.it (A.F.); maura.poli@unibs.it (M.P.);
  Tel.: +39-030-371-7303 (A.F. & M.P.); Fax: +39-030-371-7305 (A.F. & M.P.)

Received: 28 June 2017; Accepted: 3 August 2017; Published: 7 August 2017

Abstract: Recent data have indicated a fundamental role of iron in mediating a non-apoptotic and non-necrotic oxidative form of programmed cell death termed ferroptosis that requires abundant cytosolic free labile iron to promote membrane lipid peroxidation. Different scavenger molecules and detoxifying enzymes, such as glutathione (GSH) and glutathione peroxidase 4 (GPX4), have been shown to overwhelm or exacerbate ferroptosis depending on their expression magnitude. Ferroptosis is emerging as a potential weapon against tumor growth since it has been shown to potentiate cell death in some malignancies. However, this mechanism has been poorly studied in Rhabdomyosarcoma (RMS), a myogenic tumor affecting childhood and adolescence. One of the main drivers of RMS genesis is the Retrovirus Associated DNA Sequences/Extracellular signal Regulated Kinases (RAS/ERK) signaling pathway, the deliberate activation of which correlates with tumor aggressiveness and oxidative stress levels. Since recent studies have indicated that treatment with oxidative inducers can significantly halt RMS tumor progression, in this review we covered different aspects, ranging from iron metabolism in carcinogenesis and tumor growth, to mechanisms of iron-mediated cell death, to highlight the potential role of ferroptosis in counteracting RMS growth.

Keywords: iron; ferroptosis; oxidative damage; rhabdomyosarcoma

1. Introduction

Iron is the most abundant heavy metal in mammals (about 3–5 g in human adults), as it is involved in a number of biological processes, ranging from metabolism and oxygen transport to DNA synthesis and antioxidant defense. Many redox enzymes involved in cellular respiration use iron-sulfur (Fe-S) clusters as preferred cofactors, named ferredoxins, such as nicotinamide adenine dinucleotide (NADH) dehydrogenase, hydrogenases, coenzyme Q—cytochrome c reductase, succinate-coenzyme Q reductase and other components of the mitochondrial electron transport chain. In addition, heme iron is used for oxygen transport by hemoglobin and myoglobin and for the detoxification of reactive oxygen species (ROS) by catalase and superoxide dismutase enzymes. Often tumor cells show a marked alteration in metabolism leading to intracellular accumulation of iron, which is strongly utilized for tumor growth and angiogenesis [1]. Accordingly, some anti-tumor strategies using metal chelators have been successfully developed [2]; however, iron deprivation is potentially harmful to non-tumor cells, as it may favor cell death by apoptosis [3–5]. Recently, an iron-dependent type of programmed cell death has been identified, named ferroptosis [6–8]. High intracellular iron concentrations can trigger ferroptosis by enhancing the generation of lipid peroxides, and this can be reverted using iron chelators [9]. Currently, the use of ferroptosis as a weapon against tumors is of increasing interest, as tumor cells traditionally exhibit high endogenous oxidative stress levels due to gene aberrations promoting continuous cell cycles (gain of RAS, and myelocytomatosis viral related oncogene MYC) and resistance to cell senescence (P53 loss) [10]. In the next paragraphs we will describe the complex
role of iron in cancer and discuss the available evidence on iron and ferroptosis in rhabdomyosarcoma (RMS), the most frequent soft tissue tumor affecting patients of pediatric and adolescent age.

2. The Pleiotropic Role of Iron in Cancer

Deregulation of iron homeostasis may have a different impact in cancer depending on the stage of tumor progression, as summarized in Figure 1. As detailed below, iron levels influence carcinogenesis, tumor progression and sensitivity to ferroptosis.

![Figure 1](image-url)

**Figure 1.** Iron in cancer. Iron can promote carcinogenesis by oxidative stress that increases DNA damage. Following neoplastic transformation, tumors utilize various mechanisms to maintain the high intracellular iron free levels necessary for tumor growth. Over time the iron overload could become deleterious by inducing lipid peroxidation and ferroptosis.

2.1. Iron-Induced Oxidative Stress Plays a Role in Carcinogenesis

Iron overload has been associated with a higher risk of carcinogenesis, as observed in some pathological conditions, including hereditary hemochromatosis, ovarian endometriosis, chronic inflammation induced by viral hepatitis B/C, and exposure to foreign asbestos nanoparticles [11,12]. This is due to the ability of iron to promote DNA damage, as described in a model of renal carcinogenesis [13]. In particular, the most frequent DNA damage is the 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG), resulting from the oxidation of guanine, which potently induces G:C→T:A transversion mutations. Several enzymes involved in DNA repair have been identified, such as the 8-oxoguanine DNA glycosylase 1 (OGG1) [14,15] and a homologue MutT variant first isolated in a mutant strain of *E. coli* [16]. Interestingly, patients with chronic hepatitis C, who have abnormally high levels of 8-oxo-dG and repair enzymes, are protected from the formation of pre-neoplastic lesions and hepatocellular carcinoma by phlebotomy and a low iron diet [17,18]. Other studies further confirmed that phlebotomy twice a year for five years significantly protects against cancer events [19]. Altogether these data indicate that iron-induced oxidative stress can represent a critical factor for carcinogenesis induced by DNA mutagenesis [20–22].

2.2. Iron Addiction Is a Hallmark of Cancer Cells

In humans, iron homeostasis is under the control of mechanisms that coordinate the absorption, export, storage, transport and utilization of iron. The amount of iron circulating in serum and available to tissue may originate from the diet (about 1–2 mg/day), the recycling of hemoglobin by macrophages (about 20 mg/day) and hepatic stores (0.5–1 g) [23]. Iron release from these sources is controlled by hepcidin, a circulating 25 amino acid peptide hormone that reduces systemic iron availability via the binding and degradation of ferroportin (FPN), the only known cellular iron exporter [24]. Dietary iron absorption is mediated by the divalent metal transporter (DMT1) and the duodenal cytochrome b (Dcytb), both iron-regulated [25]. Plasma iron is delivered by transferrin to
all tissues presenting the transferrin receptor 1 (TfR1), which mediates its endocytosis [23]. Iron is then reduced and delivered throughout the cytosol to mitochondria for the synthesis of heme groups, Fe/S complexes and iron enzymes, whereas the excess is sequestered and stored by ferritins [26] (Figure 2). The amount of iron bound to ferritins (up to 4500 atoms) can be recycled via a recently identified mechanism mediated by a nuclear receptor coactivator 4 (NCOA4), which targets H-ferritin to lysosomal degradation [27]. As a result of these coordinated events, in non-tumor cells only a minor fraction of free labile iron is present in the cytosol, usually complexed with low molecular weight molecules including glutathione (GSH), citrate, sugars, ascorbate, nucleotides, and also enzymes [23]. On the other hand, an abnormal increase of the intracellular free iron pool is observed in cancer cells, as described in ovarian, breast, lung, prostate, and pancreatic tumors, colorectal hepatoma, gastric and hematological cancers, and melanoma [1]. This effect, commonly referred as to “iron addiction” [1], is the result of the deregulation of different mechanisms. For example, altered MYC expression, which plays a key role in cell transformation, is also responsible for iron metabolism by modulating the activity of the iron responsive protein-2 (IRP2), which in turn orchestrates the expression of different iron proteins [28]. As depicted in Figure 2, cancer cells show increased iron absorption due to high expression of TfR1, a downstream target of MYC oncoprotein [29] and hypoxia inducible factors (HIFs) [30], as observed in breast, renal, and ovarian tumors [31–33]. In addition, the down-regulation of FPN mediated by hepcidin can limit iron export [34], whereas MYC and RAS can promote the release of stored iron by the degradation of H-ferritin [35,36]. Finally, the stroma, endothelial and inflammatory cells composing the tumor niche can release iron to feed the neighboring tumor cells through a concerted upregulation of FPN and down-regulation of ferritin and heme-oxygenase [37].

![Figure 2. Iron addiction of tumor cells. In normal cells the transferrin receptor 1 (TfR1)-mediated iron absorption is counter balanced by iron efflux via ferroportin (FPN); the free iron pool is used by cytosolic and mitochondrial enzymes and the excess is stored by ferritins to prevent cytotoxicity. As a result, only a minor part of the intracellular iron, present as a free labile pool, can stimulate the formation of Reactive Oxygen Species ROS. In contrast, tumor cells often show higher levels of TfR1, down-regulation of FPN mediated by secreted hepcidin and lower levels of ferritins, which leads to an increased intracellular labile iron pool; despite this it’s mostly being utilized for tumor growth by cytosolic and mitochondrial iron enzymes, the exceeding amount can promote increased oxidative stress via ROS accumulation. The figure was adapted using a template on the servier medical art website (available online: www.servier.com) licensed under the creative commons attribution 3.0 unported license (available online: http://creativecommons.org/license/by/3.0/).](image-url)
2.3. Iron as a Trigger of Ferroptosis in Tumor Cells

Ferroptosis is an iron-dependent form of programmed cell death [6] that differs from canonical apoptosis, necrosis or autophagy in its morphological features and biochemical pathways [38–40]. As depicted in Figure 3, intracellular iron accumulation yields hydroxyl radicals via the Fenton reaction, therefore promoting the oxidation of polyunsaturated fatty acids (PUFAs, such as linoleic, arachidonic and docosahexaenoic acids). The resulting lipid peroxides and hydroperoxides [41] cause severe structural/functional alterations of cell membranes [8]. Treatments with iron chelators, antioxidant scavengers (like GSH or Vitamin E), and specific inhibitors of lipid peroxidation (like Ferrostatin-1) can prevent ferroptosis activation [6,42]. Moreover, glutathione peroxidase 4 (GPX4), a selenoprotein, protects from ferroptosis [43] as it catalyzes the endogenous neutralization of lipid hydroperoxides (L-OOH) into innocuous lipid alcohols [44,45]. Indeed, the treatment of cells with the GPX4 inhibitor RSL3 (RAS selective lethal 3) rapidly induces ferroptosis [43]. On the other hand, erastin (eradicator of RAS and ST-expressing cells) facilitates ferroptosis preferentially in RAS-positive cancer cells [46,47]. Preliminary studies have shown that erastin inhibits the membrane potential of mitochondria [48], while subsequent studies have elucidated how erastin reduces GPX4 activity [6]. Specifically erastin, similarly to sulfasalazine [6], sorafenib [49,50] and glutamate [6], inhibits cystine absorption from the extracellular space mediated by system Xc−, a glutamate-cystine antiporter [6,51]; this reduces the intracellular biosynthesis of GSH, leading to subsequent impairment of GPX4 activity. After its recent discovery in 2012, the importance of ferroptosis has attracted much interest as it represents a potential mechanism for controlling tumor growth. To date, different types of tumor have shown sensitivity to ferroptosis inducers [10], including diffuse large B-cell lymphoma, renal cell carcinoma, liver cancer, cervical carcinoma, osteosarcoma, prostate adenocarcinoma, pancreatic carcinoma, and ovarian carcinoma [43,52–54]. In addition, several proteins and pathways have been described as modulators of ferroptosis (Table 1). However, few studies have so far documented the ferroptosis process in sarcomas.

![Figure 3](image_url) **Figure 3.** Intracellular levels of iron, glutathione (GSH) and polyunsaturated fatty acids (PUFAs) influence ferroptosis. The abundant intracellular iron through the Fenton reaction can result in higher formation of hydroxyl radicals (*OH), the most reactive ROS (Reactive Oxygen Species) intermediates. These promote conversion of PUFAs into lipid hydroperoxides (L–OOH) that lead to ferroptosis. This process can be exacerbated pharmacologically by the inhibition of glutathione peroxidase 4 (GPX4), the enzyme responsible for L–OOH neutralization, by treatment with RAS selective lethal 3 (RSL3). Alternatively, GPX4 activity may be inhibited by a depletion of GSH via treatment with inhibitors of the system Xc− responsible for cystine uptake (such as erastin, sorafenib, glutamate and sulfasalazine) or with buthionine-sulfoximine (BSO), an inhibitor of the first reaction of GSH biosynthesis. The system Xc− is also transcriptionally repressed by p53. In addition, treatment with inhibitors of the mevalonate pathway, such as statins, affect GPX4 synthesis and stimulate ferroptosis. On the other hand, strategies to prevent ferroptosis include treatment with iron chelators such as deferoxamine (DFO) and neutralization of L–OOH by treatment with lipid peroxidation inhibitors (Ferrostatin-1) and antioxidant scavengers (GSH, Vitamin E).
Table 1. Proteins and pathways modulating ferroptosis.

| Pro-Ferroptosis | Function | References |
|-----------------|----------|------------|
| ACSL4           | Acyl-CoA synthase long-chain 4 increases the fraction of long polyunsaturated ω6 fatty acids in cellular membranes | [55] |
| CARS            | Cysteinyl-tRNA synthetase is an enzyme involved in charging of tRNAs with cysteine for protein translation | [56] |
| Glu             | Glutamine via glutaminolysis is essential for ferroptosis triggered by deprivation of full amino acids or of cystine alone | [57] |
| HO-1            | Heme oxygenase-1 is a heme-degrading enzyme releasing iron | [58] |
| LOX-5           | Lipoxygenase-5 catalyzes the dioxygenation of PUFAs | [5] |
| NCOA4           | Nuclear receptor coactivator 4 promotes H-Ferritin degradation | [27,59] |
| NOX             | NADPH oxidase produces ROS species | [6] |
| PS3             | It represses the expression of SLC7A11 encoding a subunit of the system Xc | [60] |
| SAT1            | Spermidine/spermine N-acetyltransferase increases the peroxidation of arachidonic acid | [61] |
| TIR1            | Transferrin receptor 1 is involved in the iron uptake | [57] |

| Anti-Ferroptosis | Function | References |
|------------------|----------|------------|
| Ferritin         | The main intracellular iron storage protein | [62] |
| GPX4             | Glutathione peroxidase-4 is a selenoenzyme neutralizing lipid hydroperoxides | [43] |
| HSPA5            | Heat shock protein-5 prevents GPX4 degradation | [63] |
| HSPP1            | Heat shock protein β-1 protects from lipid ROS | [52] |
| IRP2             | Iron responsive protein-2 controls the transcription of TIR1, Ferritin and FFN | [62] |
| MT-1             | Metallothionein-1 binds heavy metals | [64,65] |
| Mevalonate pathway | Pathway controlling the biosynthesis of selenoproteins, such as GPX4 | [66] |
| Mitochondrial Ferritin | Iron-storage protein | [67] |
| NRF2             | Nuclear factor erythroid 2-related factor 2 drives a transcriptional antioxidant program | [68] |
| System Xc       | The antiporter involved in cystine absorption | [69] |

3. Ferroptosis and Rhabdomyosarcoma

3.1. Rhabdomyosarcoma Is a Soft Tissue Sarcoma Characterized by Oxidative Stress

Sarcomas are mesenchymal tumors originating from cell precursors committed to form fat, blood vessels, nerves, bones, muscles, deep skin tissues, and cartilage. The latest classification by the World Health Organization [69] divided sarcomas into non-soft tissue sarcomas and soft-tissue sarcomas (STS). The former includes bone sarcomas such as osteosarcoma, Ewing’s sarcoma, and chondrosarcoma; while the latter includes a family of more than 50 neoplasms representing about 20% of childhood and adolescence tumors and 1% of all adult cancers. RMS arises from cell progenitors committed to skeletal muscle [70–73] and is the most common STS in patients of pediatric and adolescent age [74,75]. RMS subdivides into four main subtypes depending on histology appearance, tumor location, age of onset, and molecular drivers (Table 2).

Table 2. Histological classification and molecular drivers of rhabdomyosarcoma (RMS).

| RMS Histotypes | % of All RMS Cases | Location | Age | Prognosis | Dominant Molecular Drivers |
|----------------|--------------------|----------|-----|----------|---------------------------|
| Embryonal      | 60%                | Genitourinary tract, head and neck, urinary bladder, prostate, biliary tract, abdomen, pelvis, retroperitoneum | <10 | favorable | Activating mutations in PDGFRA, ERBB2, FGFR4, RAS, PIK3CA [76–79] IGF-2 overexpression [80,81] Somatic mutations in p53 [62] |
| Alveolar       | 20%                | Extremities, head and neck, chest, genital organs, abdomen and anal area | 10–20 | unfavorable | Chromosomal translocation t(2;13)(q35;q14) [83,84] N-MYC overexpression [85] IGF-2 overexpression [81] |
| Pleomorphic    | 10%                | Extremities, chest and abdomen | 60–80 | unfavorable | Complex karyotypes with no recurrent structural alterations |
| Spindle cell   | 10%                | Paratesticular, head and neck | <10 and >40 | favorable (children) unfavorable (adults) | NCOA2 gene rearrangements [86] Mutations in MYOD1 [87] |

Abbreviations used are: ERBB2, erb-b2 receptor tyrosine kinase 2; FGFR4, fibroblast growth factor receptor 4; IGF-2, insulin-like growth factor 2; MYOD1, myogenic differentiation 1; NCOA2, Nuclear Receptor Coactivator 2; MYC, myelocytomatosis viral related oncogene; PDGFRA, platelet-derived growth factor receptor A; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; RAS, retrovirus-associated DNA sequences.
The two predominant histotypes are the embryonal (ERMS) and the alveolar (ARMS) forms that commonly affect children under 10 years or adolescents/young adults, respectively [88]. Currently, chemotherapy, radiotherapy, and surgery are used to treat this aggressive tumor, with a five-year survival rate of higher than 70% in patients with localized disease; however, the overall survival of patients with metastasis remains low [89,90]. Different types of molecular drivers have been identified for each RMS subtype (Table 2) [91]. The most aggressive ARMS is dominated by a chromosomal translocation t(2;13)(q35;q14) that juxtaposes the DNA binding domain of the PAX3 gene in a frame with the activation domain of the FOXO1 gene, giving rise to a Pax3-Foxo1 chimeric transcription factor that is found in 70% of ARMS cases and is considered a predictor of poor prognosis [92,93]. ERMS is the most frequent form and is characterized by activating mutations in a number of receptor and transducer molecules, which cause the deliberate activation of the extracellular regulated kinases 1/2 (ERK1/2) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signaling pathways [69,71]. Among the oncogenic transducers, RAS is considered a major driver of ERMS etiogenesis [94], as the RASG12V mutated form is sufficient to convert normal myogenic cell precursors into pre-neoplastic and neoplastic counterparts [82,95]. Accordingly, germline RAS mutations on chromosome 11p15.5 are causative of the Costello syndrome, which predisposes individuals to the formation of embryonic tumors, including ERMS [96]. Sustained RAS activation correlates with ERMS tumor risk and was shown to promote a higher rate of G→T transversions due to high ROS formation [97,98]. As a consequence, RMS tumors were reported to be sensitive to a number of oxidative inducers [97], including auranofin—an inhibitor of thioredoxin reductase [99], cervistatin—a synthetic statin causing mitochondrial impairment [100], and ouabain—a glycoside inhibiting the Na+/K+ ATPase activity (Table 3). According to these findings, the identification of oxidative-stress inducers represents a milestone for the implementation of the therapeutic regimen of RMS.

### Table 3. Oxidative stress inducers that have shown efficacy in RMS treatment.

| Agents          | Targets                                               | Reference |
|-----------------|-------------------------------------------------------|-----------|
| auranofin       | Inhibitor of thioredoxin reductase                    | [97]      |
| buthionine-sulfoximine | Inhibitor of the first step of GSH biosynthesis       | [101]     |
| cervistatin     | Synthetic statin causing mitochondrial impairment      | [97]      |
| NBDHEX          | Inhibitor of GSH transferase P1-1                     | [102]     |
| ouabain         | Inhibitor of the Na⁺/K⁺ ATPase activity               | [97]      |
| sorafenib       | Inhibitor of system Xc⁻                               | [103]     |

3.2. Ferroptosis in Rhabdomyosarcoma: State of the Art

Schott et al. found that lentiviral infection of mutated hyperactive RAS forms (NRASG12V, KRASG12V and HRASG12V) in the RMS13 cell line significantly protected against ferroptosis induced by erastin, RSL3 and auranofin, suggesting that activation of the RAS/ERK pathway may confer protection against oxidative stress [104]. However, experiments recently carried out in our laboratories indicated that RMS cell lines with higher basal RAS/ERK activity are preferentially sensitized towards ferroptosis (manuscript under preparation). Thus, more detailed studies must be carried out to verify the relationship between RAS/ERK signaling, oxidative damage and sensitivity to ferroptosis in RMS. High GSH biosynthesis was reported to be necessary for growth, detoxification, and multidrug resistance in RMS. For example, increased GSH levels and GSH-S-transferase (GSTs) activity were observed in high-grade and metastatic STS treated with doxorubicin [105], as well as in ERMS tumors resistant to doxorubicin, topotecan and vincristine [106]. Moreover, high levels of reduced GSH were found in the serum of RMS patients [107]. These findings suggest that lowering GSH levels could affect RMS survival. Recent studies showed that inhibition of the GST isoenzyme, namely GSH transferase P1-1, with 6-(7-nitro-2,1,3-benzoazadiazol-4-ylthio) hexanol (NBDHEX), potentiates cell death in RMS cells treated with chemotherapeutic agents [102]. In the context of ferroptosis, treatment of RMS with sorafenib, an inhibitor of system Xc⁻ causing the depletion of endogenous GSH, counteracts cell proliferation in vitro and xenograft tumor growth in vivo [103]. However, a Phase 2 trial study did not
show consistent effects of sorafenib in RMS tumor cohorts, nonetheless its combination with irinotecan or topotecan is being evaluated in children and young adults with refractory solid tumors [108]. Buthionine-sulfoximine (BSO) is another ferroptosis inducer, which inhibits the first reaction of GSH biosynthesis catalyzed by the γ-glutamylcysteine synthetase (γ-GCSc) [43]. BSO has been shown to be effective in reducing the tumorigenic potential of two rat RMS cell lines in vitro and in vivo[101]. Interestingly, one of the two cell lines used in this study was more resistant to the BSO treatment. Biochemical analysis revealed higher levels of γ-glutamyltranspeptidase (γ-GT) [101], a plasma membrane enzyme of the outer surface responsible for breaking down extracellular GSH to increase cystine absorption [109], ultimately leading to an increase in intracellular GSH levels. Thus, it could be argued that the higher γ-GT levels inhibit ferroptosis by increasing GSH levels. Notably, abnormally high γ-GT enzymatic levels were found in patients with high-grade and metastatic sarcomas [105]. Finally, it has been shown that the treatment of RMS cells with tunicamycin or N-glycosidase is sufficient to lower GSH levels and cause cell death, suggesting that protein N-glycosylation is required for GSH biosynthesis [110]. In this regard, the folding and auto-catalytic cleavage of γ-GT has been shown to be dependent on N-glycosylation [111], suggesting again its potential involvement in ferroptosis resistance.

4. Conclusions

Recent discoveries shed light on a peculiar iron-dependent non-apoptotic form of cell death, namely ferroptosis, the execution of which is dependent on the availability of intracellular free iron, the levels of PUFAs and the levels of enzymes of detoxification from oxidative stress. RMS tumors display hallmarks of oxidative damage, which could predict the susceptibility of RMS to a number of oxidative stress inducers. Despite the important role of iron metabolism and iron proteins in cancer, little work has been done on RMS. Therefore, we discussed the agents involved in ferroptosis activation, believing that a better understanding of this mechanism in RMS may lead to therapeutic improvements.

Acknowledgments: Funding. The work was supported by Fondazione Cariplo and Regione Lombardia project “New Opportunities and ways toward European Research Council ERC” 2014-2256 to Maura Poli We would like to thank Caterina Branca (Arizona State University, Tempe, Arizona, AZ, USA) for text proofreading.

Author Contributions: Alessandro Fanzani and Maura Poli wrote the paper and prepared the figures.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Torti, S.V.; Torti, F.M. Iron and cancer: More ore to be mined. Nat. Rev. Cancer 2013, 13, 342–355. [CrossRef] [PubMed]
2. Cazzola, M.; Bergamaschi, G.; Dezza, L.; Arosio, P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: Achievements and prospects. Blood 1990, 75, 1903–1919. [PubMed]
3. Ke, J.Y.; Cen, W.J.; Zhou, X.Z.; Li, Y.R.; Kong, W.D.; Jiang, J.W. Iron overload induces apoptosis of murine preosteoblast cells via ros and inhibition of AKT pathway. Oral Dis. 2017. [CrossRef] [PubMed]
4. Tian, Q.; Wu, S.; Dai, Z.; Yang, J.; Zheng, J.; Zheng, Q.; Liu, Y. Iron overload induced death of osteoblasts in vitro: Involvement of the mitochondrial apoptotic pathway. Peer J. 2016, 4, e2611. [CrossRef] [PubMed]
5. Li, S.W.; Liu, C.M.; Guo, J.; Marcondes, A.M.; Deeg, J.; Li, X.; Guan, F. Iron overload induced by ferric ammonium citrate triggers reactive oxygen species-mediated apoptosis via both extrinsic and intrinsic pathways in human hepatic cells. Hum. Exp. Toxicol. 2016, 35, 598–607. [CrossRef] [PubMed]
6. Dixon, S.J.; Lemberg, K.M.; Lamprecht, M.R.; Skouta, R.; Zaitsev, E.M.; Gleason, C.E.; Patel, D.N.; Bauer, A.J.; Cantley, A.M.; Yang, W.S.; et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012, 149, 1060–1072. [CrossRef] [PubMed]
7. Yang, W.S.; Stockwell, B.R. Ferroptosis: Death by lipid peroxidation. Trends Cell Biol. 2016, 26, 165–176. [CrossRef] [PubMed]
8. Gaschler, M.M.; Stockwell, B.R. Lipid peroxidation in cell death. Biochem. Biophys. Res. Commun. 2017, 482, 419–425. [CrossRef] [PubMed]
9. Cao, J.Y.; Dixon, S.J. Mechanisms of ferroptosis. Cell Mol. Life Sci. 2016, 73, 2195–2209. [CrossRef] [PubMed]
10. Yu, H.; Guo, P.; Xie, X.; Wang, Y.; Chen, G. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J. Cell Mol. Med. 2017, 21, 648–657. [CrossRef] [PubMed]
11. Toyokuni, S. Role of iron in carcinogenesis: Cancer as a ferrotoxic disease. Cancer Sci. 2009, 100, 9–16. [CrossRef] [PubMed]
12. Toyokuni, S.; Ito, F.; Yamashita, K.; Okazaki, Y.; Akatsuka, S. Iron and thiol redox signaling in cancer: An exquisite balance to escape ferroptosis. Free Radic. Biol. Med. 2017, 108, 610–626. [CrossRef] [PubMed]
13. Ebina, Y.; Okada, S.; Hamazaki, S.; Ogino, F.; Li, J.L.; Midorikawa, O. Nephrotoxicity and renal cell carcinoma after use of iron- and aluminum-nitrilotriacetate complexes in rats. J. Natl. Cancer Inst. 1986, 76, 107–113. [PubMed]
14. Van der Kemp, P.A.; Thomas, D.; Barbey, R.; de Oliveira, R.; Boiteux, S. Cloning and expression in escherichia coli of the OGG1 gene of saccharomyces cerevisiae, which codes for a dna glycosylase that excises 7,8-dihydro-8-oxoguanine and 2,6-diamino-4-hydroxy-5-N-methylformamidopyrimidine. Proc. Natl. Acad. Sci. USA 1996, 93, 5197–5202. [CrossRef] [PubMed]
15. Nash, H.M.; Bruner, S.D.; Schärer, O.D.; Kawate, T.; Addona, T.A.; Spooner, E.; Lane, W.S.; Verdine, G.L. Cloning of a yeast 8-oxoguanine DNA glycosylase reveals the existence of a base-excision DNA-repair protein superfamily. Curr. Biol. 1996, 6, 968–980. [CrossRef]
16. Aburatani, H.; Hippo, Y.; Ishida, T.; Takashima, R.; Matsuba, C.; Kodama, T.; Takao, M.; Yasui, A.; Yamamoto, K.; Asano, M. Cloning and characterization of mammalian 8-hydroxyguanine-specific DNA glycosylase/apurinic, apyrimidinic lyase, a functional mutm homologue. Cancer Res. 1997, 57, 2151–2156. [PubMed]
17. Kato, J.; Miyanishi, K.; Kobune, M.; Nakamura, T.; Takada, K.; Takimoto, K.; Kawano, Y.; Takahashi, S.; Takahashi, M.; Sato, Y.; et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J. Gastroenterol. 2007, 42, 830–836. [CrossRef] [PubMed]
18. Kato, J.; Kobune, M.; Nakamura, T.; Uehara, S.; Takada, K.; Takimoto, R.; Sato, Y.; Fujikawa, K.; Takahashi, M.; Takayama, T.; et al. Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res. 2001, 61, 8697–8702. [PubMed]
19. Zacharski, L.R.; Chow, B.K.; Howes, P.S.; Shamayeva, G.; Baron, J.A.; Dalman, R.L.; Malenka, D.J.; Ozaki, C.K.; Lavori, P.W. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: Results from a randomized trial. J. Natl. Cancer Inst. 2008, 100, 996–1002. [CrossRef] [PubMed]
20. Kasai, H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat. Res. 1997, 387, 147–163. [CrossRef]
21. Kondo, S.; Toyokuni, S.; Tanaka, T.; Hiai, H.; Onodera, H.; Kasai, H.; Imamura, M. Overexpression of the HOGG1 gene and high 8-hydroxy-2′-deoxyguanosine (8-OHDG) lyase activity in human colorectal carcinoma: Regulation mechanism of the 8-OHDG level in DNA. Clin. Cancer Res. 2000, 6, 1394–1400. [PubMed]
22. Okamoto, K.; Toyokuni, S.; Kim, W.J.; Ogawa, O.; Kakehi, Y.; Aroa, S.; Hiai, H.; Yoshida, O. Overexpression of human mutm homologue gene messenger RNA in renal-cell carcinoma: Evidence of persistent oxidative stress in cancer. Int. J. Cancer 1996, 65, 437–441. [CrossRef]
23. Ganz, T.; Nemeth, E. Hepcidin and iron homeostasis. Biochim. Biophys. Acta 2012, 1823, 1434–1443. [CrossRef] [PubMed]
24. Nemeth, E.; Tuttle, M.S.; Powelson, J.; Vaughn, M.B.; Donovan, A.; Ward, D.M.; Ganz, T.; Kaplan, J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306, 2090–2093. [CrossRef] [PubMed]
25. Gunshin, H.; Allerson, C.R.; Polycarpou-Schwarz, M.; Rofts, A.; Rogers, J.T.; Kishi, F.; Hentze, M.W.; Rouault, T.A.; Andrews, N.C.; Hediger, M.A. Iron-dependent regulation of the divalent metal ion transporter. FEBS Lett. 2001, 509, 309–316. [CrossRef]
26. Arosio, P.; Levi, S. Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim. Biophys. Acta 2010, 1800, 783–792. [CrossRef] [PubMed]
27. Mancias, J.D.; Wang, X.; Gygi, S.P.; Harper, J.W.; Kimmelman, A.C. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature 2014, 509, 105–109. [CrossRef] [PubMed]
28. Maffettone, C.; Chen, G.; Drozdov, I.; Ouzounis, C.; Pantopoulos, K. Tumorigenic properties of iron regulatory protein 2 (IRP2) mediated by its specific 73-amino acids insert. PLoS ONE 2010, 5, e10163. [CrossRef] [PubMed]

29. O’Donnell, K.A.; Yu, D.; Zeller, K.I.; Kim, J.W.; Racke, F.; Thomas-Tikhonenko, A.; Dang, C.V. Activation of transferrin receptor 1 by c-MYC enhances cellular proliferation and tumorigenesis. Mol. Cell Biol. 2006, 26, 2373–2386. [CrossRef] [PubMed]

30. Tacchini, L.; Bianchi, L.; Bernelli-Zazzera, A.; Cairo, G. Transferrin receptor induction by hypoxia. Hif-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J. Biol. Chem. 1999, 274, 24142–24146. [CrossRef] [PubMed]

31. Habashy, H.O.; Powe, D.G.; Staka, C.M.; Rakha, E.A.; Ball, G.; Green, A.R.; Aleskandarany, M.; Paish, E.C.; Douglas Macmillan, R.; Nicholson, R.I.; et al. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res. Treat. 2010, 119, 283–293. [CrossRef] [PubMed]

32. Jeong, D.E.; Song, H.J.; Lim, S.; Lee, S.J.; Lim, J.E.; Nam, D.H.; Joo, K.M.; Jeong, B.C.; Jeon, S.S.; Choi, H.Y.; et al. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis. Oncotarget 2015, 6, 33046–33064. [CrossRef] [PubMed]

33. Basuli, D.; Tesfay, L.; Deng, Z.; Paul, B.; Yamamoto, Y.; Ning, G.; Xian, W.; McKeon, F.; Lynch, M.; Crum, C.P.; et al. Iron addiction: A novel therapeutic target in ovarian cancer. Oncogene 2017, 36, 4089–4099. [CrossRef] [PubMed]

34. Torti, S.V.; Torti, F.M. Ironing out cancer. Cancer Res. 2011, 71, 1511–1514. [CrossRef] [PubMed]

35. Wu, K.J.; Polack, A.; Dalla-Favera, R. Coordinated regulation of iron-controlling genes, H-ferritin and Irp2, by c-MYC. Science 1999, 283, 676–679. [CrossRef] [PubMed]

36. Kakhlon, O.; Gruenbaum, Y.; Cabantchik, Z.I. Repression of ferritin expression modulates cell responsiveness to H-ras-induced growth. Biochem. Soc. Trans. 2002, 30, 777–780. [CrossRef] [PubMed]

37. Corna, G.; Campana, L.; Pignatti, E.; Castiglioni, A.; Tagliafico, E.; Bosurgi, L.; Campanella, A.; Brunelli, S.; Manfredi, A.A.; Apostoli, P.; et al. Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica 2010, 95, 1814–1822. [CrossRef] [PubMed]

38. Latunde-Dada, G.O. Ferroptosis: Role of lipid peroxidation, iron and ferritinophagy. Biochim. Biophys. Acta 2017, 1861, 1893–1900. [CrossRef] [PubMed]

39. Doll, S.; Conrad, M. Iron and ferroptosis: A still ill-defined liaison. IUBMB Life 2017, 69, 423–434. [CrossRef] [PubMed]

40. Xie, Y.; Hou, W.; Song, X.; Yu, Y.; Huang, J.; Sun, X.; Kang, R.; Tang, D. Ferroptosis: Process and function. Cell Death Differ. 2016, 23, 369–379. [CrossRef] [PubMed]

41. Thomas, C.; Mackey, M.M.; Diaz, A.A.; Cox, D.P. Hydroxyl radical is produced via the fenton reaction in submitochondrial particles under oxidative stress: Implications for diseases associated with iron accumulation. Redox Rep. 2009, 14, 102–108. [CrossRef] [PubMed]

42. Skouta, R.; Dixon, S.J.; Wang, J.; Dunn, D.E.; Orman, M.; Shimada, K.; Rosenberg, P.A.; Lo, D.C.; Weinberg, J.M.; Linkermann, A.; et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 2014, 136, 4551–4556. [CrossRef] [PubMed]

43. Yang, W.S.; SriRamaratnam, R.; Welsch, M.E.; Shimada, K.; Skouta, R.; Viswanathan, V.S.; Cheah, J.H.; Clemons, P.A.; Shamiij, A.F.; Clish, C.B.; et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014, 156, 317–331. [CrossRef] [PubMed]

44. Seiler, A.; Schneider, M.; Förster, H.; Roth, S.; Wirth, E.K.; Culmsee, C.; Plesnial, N.; Kremmer, E.; Rädmark, O.; Wurst, W.; et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 2008, 8, 237–248. [CrossRef] [PubMed]

45. Ran, Q.; Liang, H.; Gu, M.; Qi, W.; Walter, C.A.; Roberts, L.J.; Herman, B.; Richardson, A.; van Remmen, H. Transgenic mice overexpressing glutathione peroxidase 4 are protected against oxidative stress-induced apoptosis. J. Biol. Chem. 2004, 279, 55137–55146. [CrossRef] [PubMed]

46. Dolma, S.; Lessnick, S.L.; Hahn, W.C.; Stockwell, B.R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003, 3, 285–296. [CrossRef]
66. Warner, G.J.; Berry, M.J.; Moustafa, M.E.; Carlson, B.A.; Hatfield, D.L.; Faust, J.R. Inhibition of selenoprotein

63. Zhu, S.; Zhang, Q.; Sun, X.; Zeh, H.J.; Lotze, M.T.; Kang, R.; Tang, D. HSPA5 regulates ferroptotic cell death

54. Greenshields, A.L.; Shepherd, T.G.; Hoskin, D.W. Contribution of reactive oxygen species to ovarian cancer

47. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

67. Wang, Y.Q.; Chang, S.Y.; Wu, Q.; Gou, Y.J.; Jia, L.; Cui, Y.M.; Yu, P.; Shi, Z.H.; Wu, W.S.; Gao, G.; et al. The

65. Sun, X.; Niu, X.; Chen, R.; He, W.; Chen, D.; Kang, R.; Tang, D. Metallothionein-1g facilitates sorafenib

64. Houessinon, A.; François, C.; Sauzay, C.; Louandre, C.; Mongelard, G.; Godin, C.; Bodeau, S.; Takahashi, S.;

61. Ou, Y.; Wang, S.J.; Li, D.; Chu, B.; Gu, W. Activation of sat1 engages polyamine metabolism with p53-mediated

60. Jiang, L.; Kon, N.; Pan, Q.; Zhang, W.; Xiang, J.; Jiang, X. Ferroptosis is an autophagic cell death process.

59. Gao, M.; Monian, P.; Pan, Q.; Zhang, W.; Xiang, J.; Jiang, X. Ferroptosis is an autophagic cell death process.

58. Kwon, M.Y.; Park, E.; Lee, S.J.; Chung, S.W. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell
dearth.

57. Gao, M.; Monian, P.; Quadri, N.; Ramasamy, R.; Jiang, X. Glutaminolysis and transferrin regulate ferroptosis.

56. Hayano, M.; Yang, W.S.; Corn, C.K.; Pagano, N.C.; Stockwell, B.R. Loss of cysteinyl-tRNA synthetase

55. Doll, S.; Proneth, B.; Tyurina, Y.Y.; Panzilius, E.; Kobayashi, S.; Ingold, I.; Irmler, M.; Beckers, J.; Aichler, M.;

53. Eling, N.; Reuter, L.; Hazin, J.; Hamacher-Brady, A.; Brady, N.R. Identification of artesunate as a specific

52. Reed, J.C.; Pellecchia, M. Ironing out cell death mechanisms.

51. Dixon, S.J.; Patel, D.N.; Welsch, M.; Skouta, R.; Lee, E.D.; Hayano, M.; Thomas, A.G.; Gleason, C.E.; Tatonetti, N.P.; Slusher, B.S.; et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 2014, 3, e02523. [CrossRef] [PubMed]

50. Louandre, C.; Ezzoukhry, Z.; Godin, C.; Saidak, Z.; Gutierrez, L.; et al. Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells.

49. Lachaier, E.; Louandre, C.; Godin, C.; Saidak, Z.; Baert, M.; Diouf, M.; Chauffert, B.; Galmiche, A. Sorafenib

48. Yagoda, N.; von Rechenberg, M.; Zaganjor, E.; Bauer, A.J.; Yang, W.S.; Fridman, D.J.; Wolpaw, A.J.; Smukste, I.;

47. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

46. Warner, G.J.; Berry, M.J.; Moustafa, M.E.; Carlson, B.A.; Hatfield, D.L.; Faust, J.R. Inhibition of selenoprotein

45. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

44. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

43. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

42. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

41. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

40. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

39. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

38. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

37. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

36. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

35. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

34. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

33. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

32. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

31. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

30. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

29. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

28. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

27. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

26. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

25. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

24. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

23. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

22. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

21. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

20. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

19. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

18. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

17. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

16. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

15. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

14. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,

13. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,
68. Sun, X.; Ou, Z.; Chen, R.; Niu, X.; Chen, D.; Kang, R.; Tang, D. Activation of the p62-KEAP1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. *Hepatology* 2016, 63, 173–184. [CrossRef] [PubMed]

69. Fletcher, C.D.M.; Bridge, J.A.; Hogendoorn, P.C.W.; Mertens, F. *Who Classification of Tumours of Soft Tissue and Bone*; IARC: Lyon, France, 2013.

70. Linardic, C.M.; Downie, D.L.; Qualman, S.; Bentley, R.C.; Counter, C.M. Genetic modeling of human rhabdomyosarcoma. *Cancer Res.* 2005, 65, 4490–4495. [CrossRef] [PubMed]

71. Hettmer, S.; Liu, J.; Miller, C.M.; Lindsay, M.C.; Sparks, C.A.; Guertin, D.A.; Bronson, R.T.; Langenau, D.M.; Wagers, A.J. Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells. *Proc. Natl. Acad. Sci. USA* 2011, 108, 20002–20007. [CrossRef] [PubMed]

72. Rubin, B.P.; Nishijo, K.; Chen, H.I.; Yi, X.; Schuetze, D.P.; Pal, R.; Prajapati, S.I.; Abraham, J.; Arenkiel, B.R.; Chen, Q.R.; et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. *Cancer Cell* 2011, 19, 177–191. [CrossRef] [PubMed]

73. Rodriguez, R.; Rubio, R.; Menendez, P. Modeling sarcomagenesis using multipotent mesenchymal stem cells. *Cell Res.* 2012, 22, 62–77. [CrossRef] [PubMed]

74. Parham, D.M.; Alaggio, R.; Coffin, C.M. Myogenic tumors in children and adolescents. *Pediatr. Dev. Pathol.* 2012, 15, 211–238. [CrossRef] [PubMed]

75. Kashi, V.P.; Hatley, M.E.; Galindo, R.L. Probing for a deeper understanding of rhabdomyosarcoma: Insights from complementary model systems. *Nat. Rev. Cancer* 2015, 15, 426–439. [CrossRef] [PubMed]

76. Shern, J.F.; Chen, L.; Chmielecki, J.; Wei, J.S.; Patidar, R.; Rosenberg, M.; Ambrogio, L.; Auclair, D.; Wang, J.; Song, Y.K.; et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. *Cancer Discov.* 2014, 4, 216–231. [CrossRef] [PubMed]

77. Skapek, S.X.; Anderson, J.; Barr, F.G.; Ladanyi, M.; Barr, F.G. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma. *Proc. Natl. Acad. Sci. USA* 1999, 96, 6324–6327. [CrossRef] [PubMed]
rhabdomyosarcoma: Focus on mycn as a biologically relevant target. *Genes Chromosomes Cancer* **2008**, *47*, 510–520. [CrossRef] [PubMed]

86. Sumegi, J.; Streblow, R.; Frayer, R.W.; Dal Cin, P.; Rosenberg, A.; Meloni-Ehrig, A.; Bridge, J.A. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX2 members of the nuclear receptor transcriptional coactivator family. *Genes Chromosomes Cancer* **2010**, *49*, 224–236. [PubMed]

87. Agaram, N.P.; Chen, C.L.; Zhang, L.; LaQuaglia, M.P.; Wexler, L.; Antonescu, C.R. Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: Evidence for a common pathogenesis. *Genes Chromosomes Cancer* **2014**, *53*, 779–787. [CrossRef] [PubMed]

88. Parham, D.M.; Barr, F.G. Classification of rhabdomyosarcoma and its molecular basis. *Adv. Anat. Pathol.* **2013**, *20*, 387–397. [CrossRef] [PubMed]

89. Ognjanovic, S.; Linabery, A.M.; Charbonneau, B.; Ross, J.A.C.P. Trends in childhood rhabdomyosarcoma incidence and survival in the united states, 1975–2005. *Cancer* **2009**, *115*, 4218–4226. [CrossRef] [PubMed]

90. Hettmer, S.; Li, Z.; Billin, A.N.; Barr, F.G.; Cornelison, D.D.; Ehrlich, A.R.; Guttridge, D.C.; Hayes-Jordan, A.; Helman, I.J.; Houghton, P.J.; et al. Rhabdomyosarcoma: Current challenges and their implications for developing therapies. *Cold Spring Harb. Perspect. Med.* **2014**, *4*, a025650. [CrossRef] [PubMed]

91. Zanola, A.; Rossi, S.; Faggi, F.; Monti, E.; Fanzani, A. Rhabdomyosarcomas: An overview on the experimental animal models. *J. Cell Mol. Med.* **2012**, *16*, 1377–1391. [CrossRef] [PubMed]

92. Shapiro, D.N.; Sublett, J.E.; Li, B.; Downing, J.R.; Naevé, C.W. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. *Cancer Res.* **1993**, *53*, 5108–5112. [PubMed]

93. Galili, N.; Davis, R.J.; Fredericks, W.J.; Mukhopadhyay, S.; Rauscher, F.J.; Emanuel, B.S.; Rovera, G.; Barr, F.G. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. *Nat. Genet.* **1993**, *5*, 230–235. [CrossRef] [PubMed]

94. Langenau, D.M.; Keefe, M.D.; Storer, N.Y.; Guyon, J.R.; Kutok, J.L.; Le, X.; Goessling, W.; Neuberg, D.S.; Kunkel, L.M.; Zon, L.I.C.P. Effects of ras on the genesis of embryonal rhabdomyosarcoma. *Genes Dev.* **2007**, *21*, 1382–1395. [CrossRef] [PubMed]

95. Olson, E.N.; Spizz, G.; Tainsky, M.A. The oncogenic forms of N-ras or H-ras prevent skeletal myoblast differentiation. *Mol. Cell Biol.* **1987**, *7*, 2104–2111. [CrossRef] [PubMed]

96. Aoki, Y.; Niihori, T.; Kawame, H.; Kurosawa, K.; Ohashi, H.; Tanaka, Y.; Filocamo, M.; Kato, K.; Suzuki, Y.; Kure, S.; et al. Germline mutations in hras proto-oncogene cause costello syndrome. *Nat. Genet.* **2005**, *37*, 1038–1040. [CrossRef] [PubMed]

97. Chang, X.; Stewart, E.; Shelat, A.A.; Qu, C.; Bahrami, A.; Hatley, M.; Wu, G.; Bradley, C.; McEvoy, J.; Pappo, A.; et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. *Cancer Cell* **2013**, *24*, 710–724. [CrossRef] [PubMed]

98. Zhang, M.; Linardic, C.M.; Kirsch, D.G. RAS and ROS in rhabdomyosarcoma. *Cancer Cell* **2013**, *24*, 689–691. [CrossRef] [PubMed]

99. Liu, Y.; Li, Y.; Yu, S.; Zhao, G. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents. *Curr. Drug Targets* **2012**, *13*, 1432–1444. [CrossRef] [PubMed]

100. Bouitbir, J.; Charles, A.L.; Echaniz-Laguna, A.; Kindo, M.; Daussin, F.; Auwerx, J.; Piquard, F.; Geny, B.; Zoll, J. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: A “mitohormesis” mechanism involving reactive oxygen species and PGC-1. *Eur. Heart J.* **2012**, *33*, 1397–1407. [CrossRef] [PubMed]

101. Castro, B.; Alonso-Varona, A.; del Olmo, M.; Bilbao, P.; Palomares, T. Role of γ-glutamyltranspeptidase on the response of poorly and moderately differentiated rhabdomyosarcoma cell lines to buthionine sulfoximine-induced inhibition of glutathione synthesis. *Anticancer Drugs* **2002**, *13*, 281–291. [CrossRef] [PubMed]

102. Pasello, M.; Manara, M.C.; Michelacci, F.; Fanelli, M.; Hattinger, C.M.; Nicoletti, G.; Landuzzi, L.; Lollini, P.L.; Caccuri, A.; Picci, P.; et al. Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: A promising therapeutic strategy. *Anul. Cell. Pathol. (AMST)* **2011**, *34*, 131–145. [CrossRef] [PubMed]

103. Maruwege, W.; D’Arcy, P.; Folin, A.; Brnjic, S.; Wejde, J.; Davis, A.; Erlandsson, F.; Bergh, J.; Brodin, B. Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling. *Onco Targets Ther.* **2008**, *1*, 67–78. [CrossRef] [PubMed]
104. Schott, C.; Graab, U.; Cuvelier, N.; Hahn, H.; Fulda, S. Oncogenic RAS mutants confer resistance of RMS13 rhabdomyosarcoma cells to oxidative stress-induced ferroptotic cell death. *Front. Oncol.* **2015**, *5*, 131. [CrossRef] [PubMed]

105. Hochwald, S.N.; Rose, D.M.; Brennan, M.F.; Burt, M.E. Elevation of glutathione and related enzyme activities in high-grade and metastatic extremity soft tissue sarcoma. *Ann. Surg. Oncol.* **1997**, *4*, 303–309. [CrossRef] [PubMed]

106. Seitz, G.; Bonin, M.; Fuchs, J.; Poths, S.; Ruck, P.; Warmann, S.W.; Armeanu-Ebinger, S. Inhibition of glutathione-s-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma. *Int. J. Oncol.* **2010**, *36*, 491–500. [CrossRef] [PubMed]

107. Zitka, O.; Skalickova, S.; Gumulec, J.; Masarik, M.; Adam, V.; Hubalek, J.; Trnkova, L.; Kruseova, J.; Eckschlager, T.; Kizek, R. Redox status expressed as GSH: GSSG ratio as a marker for oxidative stress in paediatric tumour patients. *Oncol. Lett.* **2012**, *4*, 1247–1253. [PubMed]

108. Kim, A.; Widemann, B.C.; Krailo, M.; Jayaprakash, N.; Fox, E.; Weigel, B.; Blaney, S.M. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the children’s oncology group. *Pediatr. Blood Cancer* **2015**, *62*, 1562–1566. [CrossRef] [PubMed]

109. Zhang, H.; Forman, H.J.; Choi, J. γ-glutamyl transpeptidase in glutathione biosynthesis. *Methods Enzymol.* **2005**, *401*, 468–483. [PubMed]

110. Calle, Y.; Palomares, T.; Castro, B.; del Olmo, M.; Alonso-Varona, A. Removal of N-glycans from cell surface proteins induces apoptosis by reducing intracellular glutathione levels in the rhabdomyosarcoma cell line s4mh. *Biol. Cell* **2000**, *92*, 639–646. [CrossRef]

111. West, M.B.; Wickham, S.; Quinalty, L.M.; Pavlovicz, R.E.; Li, C.; Hanigan, M.H. Autocatalytic cleavage of human γ-glutamyl transpeptidase is highly dependent on N-glycosylation at asparagine 95. *J. Biol. Chem.* **2011**, *286*, 28876–28888. [CrossRef] [PubMed]